Heyholder
‹ Activism Filings

SAMSUNG PHARMACEUTICAL.CO.,Ltd. Sale of treasury convertible bonds for KRW 2.0 billion to Triumph, No. 32 CB

SAMSUNG PHARMACEUTICAL.CO.,Ltd.· Material Event Report

AI summary · Not investment advice

The company decided to sell treasury No. 32 convertible bonds with face value of KRW 1,932,380,000 to Triumph for KRW 2.0 billion on Nov 3, 2026.

Sale amount

KRW 2.0 billion

Determined from the valuation report the day before the contract date and agreement between the parties

Key facts

% of total shares
1.08%
Total face value
KRW 21.7 billion
Conversion price per share
KRW 1,591
Convertible shares
1,214,569 shares
Conversion period
Aug 21, 2026 – Jul 21, 2030
Buyer
KRW 1.9 billionTriumph; no stated relationship with the company or largest shareholder
Sale proceeds receipt date
Nov 3, 2026
Bond type
No. 32 domestic registered-free coupon unsecured private placement convertible bond
Bond issue date
Aug 21, 2025
Maturity date
Aug 21, 2030

Commentary

AI commentary · Not investment advice

What happened

Samsung Pharm decided to sell part of its own convertible bonds (bonds that can later be turned into shares) to Triumph for KRW 2.0 billion. The bonds are the 32nd privately placed series. The face value being sold is KRW 1,932.38 million. The company had bought them back before maturity after talks with the bondholder, at a cost of KRW 1,971.03 million. The stated purpose of the sale is to secure operating funds.

In the company's terms

The series was issued on August 21, 2025 and matures on August 21, 2030. The total face value at issue was KRW 21.7 billion. The conversion price is KRW 1,591 per share.

What changes for shareholders

If the bonds being sold were fully converted, they would become 1,214,569 shares. That equals 1.08% of the total shares. The conversion request period runs from August 21, 2026 to July 21, 2030. The company expects to receive the sale proceeds on November 3, 2026.

Comments

No comments yet

Comments from shareholders will appear here.